217 results match your criteria: "Radiology and Clinical Immunology[Affiliation]"
Ann Oncol
March 2001
Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden.
Acta Oncol
November 2000
Department of Oncology, Radiology and Clinical Immunology, Akademiska Sjukhuset, University of Uppsala, Sweden.
Residual masses are frequently found in patients with aggressive lymphomas, following therapy. A study was undertaken to determine whether initial tumour size, changes during treatment, or size of the residual mass could provide prognostic information. Computed tomography (CT) examinations were carried out before, midway and after completion of chemotherapy in 37 patients with aggressive lymphoma with residual mass after treatment.
View Article and Find Full Text PDFActa Radiol
September 2000
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden.
Purpose: To evaluate the risk of needle track seeding or tumor cell implantation as the cause of locally recurrent breast cancer after breast conserving surgery.
Material And Methods: We reviewed recurrences from a consecutive series of 303 clinically nonpalpable breast cancers treated with breast conserving surgery after pre-operative localization. The median mammographic follow-up was 5.
Biometals
June 2000
Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, Sweden.
Effects of some metals on the growth of cultured human erythroleukemia K-562 cells were investigated when grown in two different types of media based upon RPMI-1640 or Ham's F-10. The study on proliferation, using RPMI-1640 supplemented with sodium selenite, selenomethionine, mercuric chloride, methylmercuric chloride and cadmium nitrate showed no inhibition of growth at concentrations of 2.5, 25, 25, 2.
View Article and Find Full Text PDFMed Oncol
August 2000
Departments of Oncology, Radiology and Clinical Immunology, Uppsala University, Akademiska sjukhuset, Uppsala, Sweden.
Patients with Hodgkin's disease (HD) or large cell lymphomas who relapse after conventional chemotherapy have a poor prognosis without high-dose chemotherapy and stem cell transplantation (HDCT). Patients who relapse after HDCT have an extremely poor outcome. In the present study we describe four patients with relapsed HD (n=1) and large cell lymphomas (n=3) after HDCT.
View Article and Find Full Text PDFPhys Med Biol
May 2000
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
A scanned proton beam yields dose distributions that in most cases are superior to passively scattered proton beams and to other external radiation treatment modalities. The present paper gives a description of the scanning system that has been developed at the Svedberg Laboratory (TSL) in Uppsala. The scanning technique and the technical design are described.
View Article and Find Full Text PDFNucl Med Biol
November 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
Monoclonal antibody (MAb) A33 was labeled with the positron emitter 76Br (T(1/2) = 16.2 h). Direct labeling was done using the conventional chloramine-T method.
View Article and Find Full Text PDFInvest Radiol
February 2000
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden.
Rationale And Objectives: To evaluate the sonographic appearance of normal prostate vascularity in dogs before and after injection of a new ultrasound contrast agent, NC100100.
Methods: Thirty-five intravenous injections of NC100100, in doses ranging from 0.00625 to 0.
Acta Radiol
January 2000
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden.
Purpose: To evaluate the effect of old mammograms on the specificity and sensitivity of radiologists in mammography screening.
Material And Methods: One hundred and fifty sets of screening mammograms were examined by 3 experienced screeners twice: once without and once in comparison with older mammograms. The films came from a population-based screening done during the first half of 1994 and comprised all 35 cancers detected during screening in 1994, 12/24 interval cancers, 14/34 cancers detected in the following screening and 89 normal mammograms.
Phys Med Biol
January 2000
Helax AB, and Department of Oncology, Radiology and Clinical Immunology, University Hospital, Akademiska sjukhuset, Uppsala, Sweden.
The implementation of two algorithms for calculating dose distributions for radiation therapy treatment planning of intermediate energy proton beams is described. A pencil kernel algorithm and a depth penetration algorithm have been incorporated into a commercial three dimensional treatment planning system (Helax-TMS, Helax AB, Sweden) to allow conformal planning techniques using irregularly shaped fields, proton range modulation, range modification and dose calculation for non-coplanar beams. The pencil kernel algorithm is developed from the Fermi Eyges formalism and Molière multiple-scattering theory with range straggling corrections applied.
View Article and Find Full Text PDFTransplantation
December 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
Normoglycemic, athymic nude mice were implanted with 3 microl (approximately 250) fetal, porcine islet-like cell clusters under the renal capsule. The angioarchitecture of the transplanted islets was studied by microvascular corrosion casts 3 or 52 weeks after implantation. Arterioles were few, and observed mainly in the older age group.
View Article and Find Full Text PDFAppl Radiat Isot
December 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
Quantification accuracy in positron emission tomography (PET) using non-pure positron emitters, such as 52Fe, may be influenced by gamma radiation emitted in the decay of these isotopes. High-energy positrons, emitted in the decay of the 52Fe-daughter 52mMn, also affect the quantification accuracy. A specific problem of the 52Fe/52mMn decay chain in vivo is that the kinetics of iron and manganese are different, and that PET cannot discriminate between the two nuclides.
View Article and Find Full Text PDFActa Oncol
July 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
Positron emission tomography (PET) is a medical imaging tool with high resolution and good quantitative properties, which makes it suitable for in vivo quantification of radioimmunotargeting agents. Most radionuclides used in radioimmunotherapy have positron-emitting analogues, which can be used for PET imaging, and this opens the possibility of performing dosimetry with PET. These isotopes, however, often emit gamma radiation and high-energy positrons in their decay, influencing the imaging properties of PET.
View Article and Find Full Text PDFActa Oncol
July 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
To optimize radioimmunotherapy, in vivo information on individual patients, such as radionuclide uptake, kinetics, metabolic patterns and optimal administration methods, is important. An overriding problem is to determine accurately the absorbed dose in the target organ as well as critical organs. Positron Emission Tomography (PET) is a superior technique to quantify regional kinetics in vivo with a spatial resolution better than 1 cm3 and a temporal resolution better than 10 s.
View Article and Find Full Text PDFRadiat Res
June 1999
Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
Radiation-induced DNA double-strand breaks (DSBs) were analyzed by separating large DNA fragments by pulsed-field gel electrophoresis. Human U-343MG glioma and K562 erythroleukemia cells were irradiated with 60Co gamma rays or nitrogen ions with high linear energy transfer (125 keV/microm). By comparing the fraction of DNA released into the gel below different size thresholds, corresponding to megabase-pair-sized DNA fragments, the relative effectiveness of the nitrogen ions was found to be dependent on both dose and the threshold size used in the evaluation.
View Article and Find Full Text PDFActa Oncol
May 1999
Department of Oncology, Radiology and Clinical Immunology, University of Uppsala, Akademiska Sjukhuset, Sweden.
High-energy protons have physical properties that virtually always will result in geometrically better dose distributions than can be achieved using photons or electrons. The clinical gains in terms of the probability of higher tumour control and/or the reduced probability of normal tissue complications are, however, not completely known. Comparative model dose planning studies using real patients offer the possibility of estimating the potential gains using a new technique.
View Article and Find Full Text PDFJ Hepatobiliary Pancreat Surg
January 1999
Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, Uppsala University Hospital, SE-75185 Uppsala, Sweden.
Opinions about the value of chemotherapy in pancreatic cancer vary from the idea that its use should be abandoned because of lack of proven efficacy and considerable toxicity to the idea that it may produce clinically meaningful responses correlated with improved survival. A systematic review of the available literature-based evidence was undertaken. The results are discussed in relation to supportive evidence from recent studies focusing on patient benefit.
View Article and Find Full Text PDF